LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

AstraZeneca PLC ADR

Cerrado

72.9 0.84

Resumen

Variación precio

24h

Actual

Mínimo

72.29

Máximo

73.15

Métricas clave

By Trading Economics

Ingresos

1.7B

3.4B

Ventas

-1.3B

14B

P/B

Media del Sector

29.004

51.198

BPA

0.934

Rentabilidad por dividendo

2.15

Margen de beneficios

25.037

Empleados

94,300

EBITDA

610M

5B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+20.44% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.15%

2.40%

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

7.5B

224B

Apertura anterior

72.06

Cierre anterior

72.9

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

AstraZeneca PLC ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 may 2025, 09:36 UTC

Principales Movimientos del Mercado

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

29 abr 2025, 10:14 UTC

Ganancias

Correction to AstraZeneca Update

29 abr 2025, 09:15 UTC

Ganancias

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- 2nd Update

29 abr 2025, 08:12 UTC

Ganancias

AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China -- Update

29 abr 2025, 06:32 UTC

Ganancias

AstraZeneca Sales, Earnings Rise

24 mar 2025, 03:15 UTC

Principales Movimientos del Mercado

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

28 may 2025, 18:09 UTC

Ganancias

Heart Disease Could Be a Goner When These New -2-

28 may 2025, 18:09 UTC

Ganancias

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

20 may 2025, 06:09 UTC

Adquisiciones, fusiones, absorciones

AstraZeneca Completes Acquisition of EsoBiotec

12 may 2025, 12:07 UTC

Charlas de Mercado

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 may 2025, 07:20 UTC

Charlas de Mercado

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

8 may 2025, 15:20 UTC

Ganancias

Trump Announces U.S.-U.K. Trade Deal. Most Tariffs Aren't Coming Down. -- Barrons.com

29 abr 2025, 13:09 UTC

Charlas de Mercado
Ganancias

AstraZeneca's Oncology Miss Doesn't Dent Positive Outlook -- Market Talk

29 abr 2025, 08:04 UTC

Charlas de Mercado
Ganancias

AstraZeneca's Results Provide a Mixed Picture -- Market Talk

29 abr 2025, 06:05 UTC

Ganancias

AstraZeneca 1Q Core EPS $2.49

29 abr 2025, 06:04 UTC

Ganancias

AstraZeneca 1Q Net Pft $2.92B

29 abr 2025, 06:02 UTC

Ganancias

AstraZeneca: Committed to Further Invest and Grow in the U.S.

29 abr 2025, 06:00 UTC

Ganancias

AstraZeneca 1Q Core EPS Consensus Was $2.27

29 abr 2025, 06:00 UTC

Ganancias

AstraZeneca 1Q Revenue Consensus Was $13.80B

29 abr 2025, 06:00 UTC

Ganancias

AstraZeneca Backs 2025 View

29 abr 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q EPS $1.87

29 abr 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Rev $13.59B

29 abr 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Oper Pft $3.67B

29 abr 2025, 06:00 UTC

Ganancias

AstraZeneca PLC 1Q Pretax Pft $3.4B

15 abr 2025, 09:55 UTC

Charlas de Mercado

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

9 abr 2025, 07:23 UTC

Charlas de Mercado

Pharma Stocks Tumble After Trump Floats Tariffs on Industry -- Market Talk

3 abr 2025, 08:41 UTC

Charlas de Mercado

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 abr 2025, 08:36 UTC

Charlas de Mercado

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3 abr 2025, 07:51 UTC

Charlas de Mercado

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31 mar 2025, 09:31 UTC

Acciones populares

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

Comparación entre iguales

Cambio de precio

AstraZeneca PLC ADR previsión

Precio Objetivo

By TipRanks

20.44% repunte

Estimación a 12 Meses

Media 87.14 USD  20.44%

Máximo 97 USD

Mínimo 75 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 69.55Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.